Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-4362.2003.01184.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-27 as a novel biomarker for pruritus in nodular prurigo and bullous pemphigoid.
Front Immunol
December 2024
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Bullous pemphigoid (BP) and prurigo nodularis (PN) are chronic pruritic skin diseases that severely impact patients' quality of life. Despite the widespread attention these two diseases have garnered within the dermatological field, the specific pathogenesis, particularly the molecular mechanisms underlying the pruritus, remains largely unclear. Limited clinical sequencing studies focusing on BP and PN have hindered the identification of pathological mechanisms and the exploration of effective treatment strategies.
View Article and Find Full Text PDFAn Atypical Manifestation: Linear Hyperkeratotic Prurigo Nodularis.
Cureus
November 2024
Dermatology, Mosaic Dermatology, Houston, USA.
We present the case of a 42-year-old Indian male with prurigo nodularis, exhibiting multiple verrucous, brownish-black nodules on the left lower and right upper extremities, with milder involvement of the right lower extremity. The lesions were asymmetrically distributed in a near-linear pattern, with prominent white hyperkeratosis and associated moderate pruritus and paresthesia. Differential diagnoses included pemphigoid nodularis, verruca vulgaris, and hypertrophic lichen planus, with a biopsy confirming prurigo nodularis.
View Article and Find Full Text PDFEfficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 Trial.
JAMA Dermatol
November 2024
Department of Dermatology, University of Maryland School of Medicine, Baltimore.
Importance: Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a previous 16-week phase 3 study (OLYMPIA 2).
Objective: To assess the efficacy and occurrence of adverse events in adults with moderate to severe PN treated with nemolizumab vs those receiving placebo.
Proposed therapeutic and care approach in a patient with chronic prurigo: Clinical case.
Enferm Clin (Engl Ed)
December 2024
Departamento de Enfermería, Facultad de Ciencias de la Salud, Universidad de Jaén, Jaén, Spain.
We present the clinical case of an 87-year-old man who presents with chronic prurigo without skin treatment. The aim is to apply an individualized care plan that allows, based on the latest evidence, to achieve skin integrity, which is deteriorated, and improve its quality of life due to the current failure toad dress the pathology. Several NANDA International diagnostic labels were identified using the NNNConsult online tool and the expected outcomes were plan along with the planned nursing interventions.
View Article and Find Full Text PDFGreater Auricular Trophic Syndrome Following Parotidectomy.
WMJ
November 2024
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Article Synopsis
- - Trigeminal trophic syndrome leads to self-inflicted skin lesions due to nerve damage, while greater auricular trophic syndrome can develop after nerve sacrifice during parotid surgery.
- - A 59-year-old woman experienced ear ulceration five months post-parotidectomy, diagnosed with greater auricular trophic syndrome and treated effectively with topical clobetasol and behavioral changes.
- - Unlike other reported cases that involved mental health issues, this case involved a patient without prior psychiatric disorders, demonstrating successful treatment focusing on physical symptoms rather than psychological factors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!